<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.103047</article-id><article-id pub-id-type="publisher-id">ACM-34695</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200300000_30372698.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  神经外科重症监护病房患者血清降钙素原水平在颅内感染诊断中的应用价值
  Determination ofNICU Procalcitonin Level and Clinical Application of Infection Diagnosis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>肖</surname><given-names>现</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>何</surname><given-names>强华</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>松青</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>扬</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>华</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>爱华</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>彭</surname><given-names>玉洁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>潘</surname><given-names>宏华</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>中国人民解放军南部战区海军第一医院神经外科，广东 湛江</addr-line></aff><aff id="aff3"><addr-line>中国人民解放军第924医院神经康复科，广西 桂林</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>03</month><year>2020</year></pub-date><volume>10</volume><issue>03</issue><fpage>295</fpage><lpage>300</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   目的：本研究旨在探讨神经外科重症监护病房(NICU)患者血清降钙素原水平在颅内感染诊断中的临床应用价值。方法：回顾性分析2年内在中国人民解放军第422医院NICU中接受血清降钙素原测定的神经外科患者的降钙素原水平。血清降钙素原水平 ≥ 0.2 ng/mL认定为阳性结果通过临床和/或微生物学诊断感染。以血清降钙素原水平 ≥ 0.2 ng/mL评估临床或微生物感染诊断的敏感性、特异性、阳性预测值和阴性预测值。结果：本研究的163名患者中，51名患者降钙素原测定阳性，降钙素原水平 &gt; 0.2 ng/mL与感染无显著相关性。降钙素原水平 &gt; 0.2 ng/mL的假阴性率为37.4%，假阳性率为11.0%，敏感性为35.1％，特异性为64.7%，阳性预测值为73.9%，阴性预测值为45.5%。结论：血清降钙素原作为生物标志物在NICU患者中诊断颅内感染的效用有限，应谨慎和有选择地使用血清降钙素原测定诊断颅内感染。 Objective: The purpose of this study was to investigate the clinical value of serum procalcitonin levels in the diagnosis of intracranial infections in the Neurosurgical Intensive Care Unit (NICU). Methods: Retrospective analysis of procalcitonin levels in neurosurgical patients who received procalcitonin in the NICU of the 105th Hospital of Chinese People’s Liberation Army within 2 years. Serum procalcitonin levels ≥ 0.2 ng / mL were considered positive and were diagnosed by clinical and/or microbiological diagnosis. To assess the sensitivity, specificity, positive predictive value, and negative predictive value of clinical or microbial infection diagnosis with serum procalcitonin level ≥ 0.2 ng/mL. Results: Of the 163 patients in the study, 51 patients had positive procalcitonin measurements, and procalcitonin levels &gt; 0.2 ng/mL were not significantly associated with infection. Procalcitonin levels &gt; 0.2 ng/mL. The false negative rate was 37.4%, the false positive rate was 11.0%, the sensitivity was 35.1%, the specificity was 64.7%, the positive predictive value was 73.9%, and the negative predictive value was 45.5%. Conclusion: Procalcitonin as a biomarker has limited utility in diagnosing intracranial infections in NICU patients. Care should be taken to use a procalcitonin assay to diagnose intracranial infections with caution and selectivity. 
 
</p></abstract><kwd-group><kwd>血清降钙素原，颅内感染，重症监护病房，神经外科, Procalcitonin</kwd><kwd> Intracranial Infection</kwd><kwd> NICU</kwd><kwd> Neurosurgery</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>神经外科重症监护病房患者血清降钙素原水平在颅内感染诊断中的应用价值<sup> </sup></title><p>肖现<sup>1*</sup>，何强华<sup>1</sup>，王松青<sup>1</sup>，李扬<sup>1</sup>，杨华<sup>1</sup>，张爱华<sup>1</sup>，彭玉洁<sup>1</sup>，潘宏华<sup>2*</sup></p><p><sup>1</sup>中国人民解放军南部战区海军第一医院神经外科，广东 湛江</p><p><sup>2</sup>中国人民解放军第924医院神经康复科，广西 桂林</p><disp-formula id="hanspub.34695-formula214"><graphic xlink:href="//html.hanspub.org/file/21-1571176x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年3月2日；录用日期：2020年3月17日；发布日期：2020年3月24日</p><disp-formula id="hanspub.34695-formula215"><graphic xlink:href="//html.hanspub.org/file/21-1571176x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：本研究旨在探讨神经外科重症监护病房(NICU)患者血清降钙素原水平在颅内感染诊断中的临床应用价值。方法：回顾性分析2年内在中国人民解放军第422医院NICU中接受血清降钙素原测定的神经外科患者的降钙素原水平。血清降钙素原水平 ≥ 0.2 ng/mL认定为阳性结果通过临床和/或微生物学诊断感染。以血清降钙素原水平 ≥ 0.2 ng/mL评估临床或微生物感染诊断的敏感性、特异性、阳性预测值和阴性预测值。结果：本研究的163名患者中，51名患者降钙素原测定阳性，降钙素原水平 &gt; 0.2 ng/mL与感染无显著相关性。降钙素原水平 &gt; 0.2 ng/mL的假阴性率为37.4%，假阳性率为11.0%，敏感性为35.1％，特异性为64.7%，阳性预测值为73.9%，阴性预测值为45.5%。结论：血清降钙素原作为生物标志物在NICU患者中诊断颅内感染的效用有限，应谨慎和有选择地使用血清降钙素原测定诊断颅内感染。</p><p>关键词 :血清降钙素原，颅内感染，重症监护病房，神经外科</p><disp-formula id="hanspub.34695-formula216"><graphic xlink:href="//html.hanspub.org/file/21-1571176x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/21-1571176x8_hanspub.png" /> <img src="//html.hanspub.org/file/21-1571176x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>血清降钙素原是一种血流炎症生物标志物 [<xref ref-type="bibr" rid="hanspub.34695-ref1">1</xref>]，已被证实可用于医疗和外科重症监护病房(ICU)患者败血症的诊断。尽管血清降钙素原在危重病人的细菌感染诊断中应用前景广阔，但由于血清降钙素原水平在许多非传染性疾病中存在，包括创伤、手术、严重烧伤和部分肿瘤 [<xref ref-type="bibr" rid="hanspub.34695-ref1">1</xref>]，因此使得这种标记物的临床应用变得复杂。颅内感染在神经外科手术后常有发生，相关文章报道神经外科手术后颅内感染发生率大概为0.2%~0.4%，患者死亡率约为58% [<xref ref-type="bibr" rid="hanspub.34695-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.34695-ref3">3</xref>]。虽然血清降钙素原的监测在外科重症监护室(ICU)患者中已有广泛的临床应用，但很少有研究评估神经外科ICU (NICU)患者的降钙素原水平在颅内感染诊断中的临床应用价值，更缺乏确切的科学研究证据。因此，本研究旨在进一步探讨神经外科重症监护病房(NICU)患者血清降钙素原水平在颅内感染诊断中的临床应用价值。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>回顾性分析2016年1月1日至2017年12月31日中国人民解放军南部战区海军第一医院神经外科所有在NICU住院期间接受血清降钙素测定的患者163例，其中男91例，女72例，患者年龄平均(55 &#177; 11)岁。其中入院诊断分别为颅内病变(23.3%)、脊柱内感染(11.%)、硬膜下血肿(12.3%)、硬膜外血肿(1.2%)、脑室内出血(3.1%)、脑出血(11.0%)、蛛网膜下腔出血蛛网膜下腔出血(31.3%)、动静脉畸形破裂(1.8%)、未破裂的动脉瘤(1.8%)和其它(2.5%)。本研究经过我院伦理委员会审核和批准。</p></sec><sec id="s4_2"><title>2.2. 纳入和排除标准</title><p>纳入标准：1) 所有患者签署知情同意书和愿意配合研究工作；2) 年龄 ≥ 18岁；3) 有颅内感染临床症状及体征。排除标准：1) 未签署知情同意书；2) 妊娠女性；3) 入院前已明确诊断其他系统感染者。</p></sec><sec id="s4_3"><title>2.3. 研究方法</title><p>用酶联免疫荧光法测量所有纳入研究标准的患者的血清降钙素原水平，根据临床诊断分组。以血清降钙素原0.2 ng/ml为标准 [<xref ref-type="bibr" rid="hanspub.34695-ref4">4</xref>]，分为≥0.2 ng/ml和&lt;0.2 ng/ml组。结合临床和或微生物诊断颅内感染，进而分析血清降钙素原诊断颅内感染的灵敏性，特异性和预测值。</p></sec><sec id="s4_4"><title>2.4. 统计分析</title><p>数据采用SPSS 20.0统计学软件进行统计分析，数据以平均数&#177;标准差( x &#175; &#177; s )，组间比较采用ANOVA检验和秩和检验，分类资料以率表示，进行χ2检验。两组数据采用t检验，以P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 研究人群和临床因素</title><p>分析发现，163名NICU患者接受了降钙素原的治疗，其中94名记录有感染(57.7%)，51名患者降钙素原测定阳性(31.3%)。该研究人群平均年龄为55岁，女性为44.2%。在检测降钙素原时，35%已接受全身抗生素治疗，38%接受糖皮质激素治疗。见表1。最常见的入院诊断为蛛网膜下腔出血(31.3%)，非血管非感染性颅内病变(19.0%)，脑出血(11.0%)和硬膜下血肿(12.3%)。见表2。降钙素原检测人群中符合SIRS标准的最多(33.7%)，其次是没有SIRS标准或特定疑似来源(白细胞升高，持续发热或神经系统改变；32.5%)的一般全身或神经系统症状。见表3。</p></sec><sec id="s5_2"><title>3.2. 双变量分析</title><p>以下变量与临床诊断或微生物学证实的感染显著相关：全身性抗生素治疗(P &lt; 0.0001)，住院期间死亡(P = 0.005)和ICU住院时间(P &lt; 0.0001)。降钙素原水平 &gt; 0.2 ng/mL (P = 0.26)，平均最高温度(P = 0.45)，白细胞(P = 0.46)，中性粒细胞百分比(P = 0.82)，接受全身性糖皮质激素治疗(P = 0.53)年龄(P = 0.64)和性别与感染无显著相关性。</p></sec><sec id="s5_3"><title>3.3. 降钙素原测定的灵敏性，特异性和预测值</title><p>计算预测率以确定真阳性(n = 33; 20.2%)，真阴性(n = 51; 31.3%)，假阳性(n = 18; 11.0%)和假阴性(n = 61; 37.4%)。降钙素原水平&gt; 0.2 ng/mL对感染诊断的灵敏性为35.1% (95%CI, 25.3%~44.9%)，特异性为64.7% (95%CI, 51.1%~78.3%)，阳性预测值为73.9% (95%CI, 63.3%~84.5%)，阴性预测值为45.5% (~95%CI, 36.1%~54.9%)。</p><p>还对符合SIRS标准的患者进行了亚组分析，其中WBC呈上升趋势，或具有持续性特征。在这一人群中，有20个真阳性(18.3%)，41个真阴性(38.0%)，14个假阳性(12.7%)和33个假阴性(31.0%)。在该子集中，降钙素原水平 &gt; 0.2 ng/mL对诊断感染的敏感性为37.7% (95%CI, 24.2%~51.2%)，特异性为74.5% (95%CI, 62.6%~86.4%)阳性预测值为58.8% (95%CI, 41.4%~76.3%)，阴性预测值为55.4% (95%CI, 43.8%~67.0%)。见表4。</p><p>为了排除在降钙素原作用之前开始抗生素治疗可能导致我们的患者群体出现假阴性结果的可能性，我们对那些符合SIRS标准的患者进行了亚组分析，这些患者的WBC上升或持续发热没有接受过抗生素治疗。该亚组的ROC分析产生的AUC为0.68，与我们的初始计算相似。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of general data for procalcitonin determinatio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >总队列(N = 163)</th><th align="center" valign="middle" >降钙素原 &lt; 0.2 ng/Ml (N = 120)</th><th align="center" valign="middle" >降钙素原 ≥ 0.2 ng/mL (N = 43)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >55.18 &#177; 11.62</td><td align="center" valign="middle" >54.93 &#177; 11.48</td><td align="center" valign="middle" >55.88 &#177; 12.13</td><td align="center" valign="middle" >0.64</td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >91</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >72</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >NICU住院时间/天</td><td align="center" valign="middle" >35.37 &#177; 17.11</td><td align="center" valign="middle" >36.42 &#177; 16.77</td><td align="center" valign="middle" >32.41 &#177; 17.90</td><td align="center" valign="middle" >0.19</td></tr><tr><td align="center" valign="middle" >抗生素治疗</td><td align="center" valign="middle" >57 (35.0%)</td><td align="center" valign="middle" >40 (33.3%)</td><td align="center" valign="middle" >15 (34.9%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >糖皮质激素治疗</td><td align="center" valign="middle" >62 (38.0%)</td><td align="center" valign="middle" >48 (40%)</td><td align="center" valign="middle" >17 (39.5%)</td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表1. 降钙素原测定一般资料比较</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of admission diagnosis and procalcitonin measuremen</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >入院诊断</th><th align="center" valign="middle" >总队列(N = 163)</th><th align="center" valign="middle" >降钙素原 &lt; 0.2 ng/Ml (N = 120)</th><th align="center" valign="middle" >降钙素原 ≥ 0.2 ng/mL (N = 43)</th></tr></thead><tr><td align="center" valign="middle" >颅内病变，非感染性</td><td align="center" valign="middle" >31 (19.0)</td><td align="center" valign="middle" >22 (18.3)</td><td align="center" valign="middle" >8 (18.6)</td></tr><tr><td align="center" valign="middle" >脊柱病变，非感染性</td><td align="center" valign="middle" >15 (9.2)</td><td align="center" valign="middle" >8 (6.7)</td><td align="center" valign="middle" >6 (14.0)</td></tr><tr><td align="center" valign="middle" >颅内病变，感染性</td><td align="center" valign="middle" >7 (4.3)</td><td align="center" valign="middle" >6 (5.0)</td><td align="center" valign="middle" >2 (4.7)</td></tr><tr><td align="center" valign="middle" >脊柱病变，感染性</td><td align="center" valign="middle" >4 (2.5)</td><td align="center" valign="middle" >3 (2.5)</td><td align="center" valign="middle" >1 (2.3)</td></tr><tr><td align="center" valign="middle" >硬膜下血肿</td><td align="center" valign="middle" >20 (12.3)</td><td align="center" valign="middle" >16 (13.3)</td><td align="center" valign="middle" >4 (9.3)</td></tr><tr><td align="center" valign="middle" >硬膜外血肿</td><td align="center" valign="middle" >2 (1.2)</td><td align="center" valign="middle" >2 (1.7)</td><td align="center" valign="middle" >1 (2.3)</td></tr><tr><td align="center" valign="middle" >脑室内出血</td><td align="center" valign="middle" >5 (3.1)</td><td align="center" valign="middle" >4 (3.3)</td><td align="center" valign="middle" >0 (0)</td></tr><tr><td align="center" valign="middle" >脑出血</td><td align="center" valign="middle" >18 (11.0)</td><td align="center" valign="middle" >15 (12.5)</td><td align="center" valign="middle" >6 (14.0)</td></tr><tr><td align="center" valign="middle" >蛛网膜下腔出血</td><td align="center" valign="middle" >51 (31.3)</td><td align="center" valign="middle" >38 (31.7)</td><td align="center" valign="middle" >13 (30.2)</td></tr><tr><td align="center" valign="middle" >动静脉畸形，破裂</td><td align="center" valign="middle" >3 (1.8)</td><td align="center" valign="middle" >3 (2.5)</td><td align="center" valign="middle" >0 (0)</td></tr><tr><td align="center" valign="middle" >未破裂的动脉瘤</td><td align="center" valign="middle" >3 (1.8)</td><td align="center" valign="middle" >2 (1.7)</td><td align="center" valign="middle" >1 (2.3)</td></tr><tr><td align="center" valign="middle" >其它</td><td align="center" valign="middle" >4 (2.5)</td><td align="center" valign="middle" >1 (0.8)</td><td align="center" valign="middle" >1 (2.3)</td></tr></tbody></table></table-wrap><p>表2. 入院诊断与降钙素原测定比较</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of diagnosis results of various systems and procalcitoni</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >总队列(N = 163)</th><th align="center" valign="middle" >降钙素原 &lt; 0.2 ng/Ml (N = 120)</th><th align="center" valign="middle" >降钙素原 ≥ 0.2 ng/mL (N = 43)</th></tr></thead><tr><td align="center" valign="middle" >SIRS标准</td><td align="center" valign="middle" >55 (33.7)</td><td align="center" valign="middle" >36 (30.0)</td><td align="center" valign="middle" >13 (30.2)</td></tr><tr><td align="center" valign="middle" >肺部</td><td align="center" valign="middle" >16 (9.8)</td><td align="center" valign="middle" >12 (10.0)</td><td align="center" valign="middle" >5 (11.6)</td></tr><tr><td align="center" valign="middle" >腹部/腹泻</td><td align="center" valign="middle" >1 (0.6)</td><td align="center" valign="middle" >1 (0.8)</td><td align="center" valign="middle" >0 (0)</td></tr><tr><td align="center" valign="middle" >颅</td><td align="center" valign="middle" >3 (1.8)</td><td align="center" valign="middle" >2 (1.7)</td><td align="center" valign="middle" >1 (2.3)</td></tr><tr><td align="center" valign="middle" >尿</td><td align="center" valign="middle" >3 (1.8)</td><td align="center" valign="middle" >2 (1.7)</td><td align="center" valign="middle" >1 (2.3)</td></tr><tr><td align="center" valign="middle" >决定停止使用抗生素</td><td align="center" valign="middle" >3 (1.8)</td><td align="center" valign="middle" >2 (1.7)</td><td align="center" valign="middle" >2 (4.6)</td></tr><tr><td align="center" valign="middle" >在没有SIRS的情况下，WBC升高， 持续发热或神经系统改变</td><td align="center" valign="middle" >53 (32.5)</td><td align="center" valign="middle" >44 (36.7)</td><td align="center" valign="middle" >11 (25.6)</td></tr><tr><td align="center" valign="middle" >其它</td><td align="center" valign="middle" >13 (8.0)</td><td align="center" valign="middle" >14 (11.7)</td><td align="center" valign="middle" >0 (0)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >16 (9.8)</td><td align="center" valign="middle" >7 (5.8)</td><td align="center" valign="middle" >10 (23.3)</td></tr></tbody></table></table-wrap><p>表3. 各系统诊断结果与降钙素原测定分类比较</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Sensitivity and specificity of serum procalcitonin to diagnose infectio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >病人</th><th align="center" valign="middle" >病人数</th><th align="center" valign="middle" >真阳性</th><th align="center" valign="middle" >真阴性</th><th align="center" valign="middle" >假阳性</th><th align="center" valign="middle" >假阴性</th><th align="center" valign="middle" >敏感性 (95% CI)</th><th align="center" valign="middle" >特异性 (95% CI)</th><th align="center" valign="middle" >阳性预测值 (95% CI)</th><th align="center" valign="middle" >阴性预测值 (95% CI)</th></tr></thead><tr><td align="center" valign="middle" >所有病人</td><td align="center" valign="middle" >163</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >35.1 (25.3~44.9)</td><td align="center" valign="middle" >64.7 (51.1~78.3)</td><td align="center" valign="middle" >73.9 (63.3~84.5)</td><td align="center" valign="middle" >45.5 (36.1~54.9)</td></tr><tr><td align="center" valign="middle" >SIRS/发热/WBC升高</td><td align="center" valign="middle" >108</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >33</td><td align="center" valign="middle" >37.7 (24.2~51.2)</td><td align="center" valign="middle" >74.5 (62.6~86.4)</td><td align="center" valign="middle" >58.8 (41.4~76.3)</td><td align="center" valign="middle" >55.4 (43.8~67.0)</td></tr><tr><td align="center" valign="middle" >未服用抗生素</td><td align="center" valign="middle" >79</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >39</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >40.0 (21.4~58.6)</td><td align="center" valign="middle" >79.6 (67.9~91.3)</td><td align="center" valign="middle" >54.5 (31.9~77.1)</td><td align="center" valign="middle" >68.4 (56.0~80.9)</td></tr><tr><td align="center" valign="middle" >未服用类固醇</td><td align="center" valign="middle" >71</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >22</td><td align="center" valign="middle" >38.9 (22.1~55.6)</td><td align="center" valign="middle" >71.4 (55.7~87.2)</td><td align="center" valign="middle" >58.3 (37.1~79.6)</td><td align="center" valign="middle" >53.2 (38.4~68.0)</td></tr></tbody></table></table-wrap><p>表4. 血清降钙素原诊断感染的敏感性和特异性</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>目前，降钙素原是用于预测和诊断血流细菌感染最有价值和广泛使用的生物标志物之一 [<xref ref-type="bibr" rid="hanspub.34695-ref5">5</xref>]。降钙素原检测也被广泛用于下呼吸道感染的诊断，降钙素原指导下的抗生素治疗使得抗生素的使用减少、等效死亡率和治疗失败率减少 [<xref ref-type="bibr" rid="hanspub.34695-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.34695-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.34695-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.34695-ref9">9</xref>]。一些研究评估了降钙素在神经外科患者脓毒症诊断的可靠性，但结果各不相同。一项研究报告指出，aSAH患者的降钙素原水平在感染和未感染患者中没有统计学差异 [<xref ref-type="bibr" rid="hanspub.34695-ref10">10</xref>]，而另一项报告针对aSAH患者的研究发现，降钙素原是该人群中感染的高度特异性预测因子，AUC为0.96 [<xref ref-type="bibr" rid="hanspub.34695-ref11">11</xref>]。因此，神经外科患者仍缺乏明确的降钙素原水平指导的抗生素治疗方案。此外，颅脑损伤术后患者因合并下丘脑损伤会引起中枢性高热，而且术后可以出现吸收热 [<xref ref-type="bibr" rid="hanspub.34695-ref12">12</xref>]，这些都是感染诊断的误导因素。</p><p>王广涛 [<xref ref-type="bibr" rid="hanspub.34695-ref13">13</xref>] 从98例脑外伤患者病例总结认为：脑外伤术后颅内感染患者血清降钙素原含量上升，且上升程度与患者病情严重程度呈正相关。黄永福 [<xref ref-type="bibr" rid="hanspub.34695-ref14">14</xref>] 等通过多因素分析的研究显示，开颅手术、CT可见脑挫伤灶、多发伤是伤后第1周降钙素原升高的独立危险因素，提示外科手术和严重创伤可导致降钙素原升高。以上研究提示降钙素原的水平作为NICU患者颅内感染的诊断标准还需要进一步验证。</p><p>在我们的研究中降钙素原水平 &gt; 0.2 ng/mL与颅内感染无显著相关性(P = 0.25)。这个结果并不意味着降钙素原在所有患者中缺乏临床效用，我们提倡使用降钙素原的检测方案，但需要对这些复杂的神经外科重症监护病房(NICU)患者进行前瞻性研究，以更好地确定可能具有临床实用价值的降钙素原值。</p><p>本研究中，正如其他重症患者群体所证明的那样，我们试图评估降钙素原水平是否能够反映了颅内感染。然而，这项观察性研究有一些局限性，由于是回顾性研究，数据的报告和收集可能存在不准确之处。神经外科医生对降钙素原测定结果的解释各不相同。这些研究结果是否准确反映了其他机构使用降钙素原测定的情况也不清楚。此外，任何观察性研究的诊断精确性都受到来自金标准标记物偏见影响。</p><p>尽管存在这些局限性，我们的研究提供了一些关键见解。我们试图准确反映降钙素原检测在实践中的应用价值，此前神经外科患者中尚未详细报道过。因此，在我们观察的人群中降钙素原测定的效用在逐渐降低，并不令人惊讶。最关键的是，我们发现，降钙素原测定不足以作为诊断神经外科患者感染的独立标记物。</p></sec><sec id="s7"><title>5. 结论</title><p>综上所述，我们的研究结果需要进行额外的前瞻性研究支持，以进一步说明在NICU患者中降钙素原水平的临床相关性以及基于降钙素原测定结果的抗菌方案的效用。在进一步研究完成之前，在使用降钙素原作为神经外科重症监护病房人群的临床决策工具时，应谨慎行事。</p></sec><sec id="s8"><title>文章引用</title><p>肖 现,何强华,王松青,李 扬,杨 华,张爱华,彭玉洁,潘宏华. 神经外科重症监护病房患者血清降钙素原水平在颅内感染诊断中的应用价值Determination ofNICU Procalcitonin Level and Clinical Application of Infection Diagnosis[J]. 临床医学进展, 2020, 10(03): 295-300. https://doi.org/10.12677/ACM.2020.103047</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.34695-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Talan, D.A. (2015) Procalcitonin Is Not a Useful Biomarker of Sepsis. Annals of Emergency Medicine, 66, 320-321. &lt;br&gt;https://doi.org/10.1016/j.annemergmed.2015.03.010</mixed-citation></ref><ref id="hanspub.34695-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">张冬惠, 徐莉娜, 王绍谦, 等. 降钙素原对诊治脑出血微创术后合并颅内感染的影响[J]. 医学综述, 2015, 21(8): 1524-1525.</mixed-citation></ref><ref id="hanspub.34695-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">王静, 刘春, 孟宪红, 等. 血清降钙素原对脑出血患者微创术后伴颅内感染的诊治评价[J]. 中华医院感染学杂志, 2016, 26(1): 46-48.</mixed-citation></ref><ref id="hanspub.34695-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">阮文清. 定量检测降钙素原在患者感染诊断及预后判断中的临床价值探究[J]. 中国医药指南, 2013, 11(8): 94-95.</mixed-citation></ref><ref id="hanspub.34695-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Dandona, P., et al. (1994) Procalcitonin Increase after Endotoxin Injection in Normal Subjects. The Journal of Clinical Endocrinology and Metabolism, 79, 1605-1608. &lt;br&gt;https://doi.org/10.1210/jc.79.6.1605</mixed-citation></ref><ref id="hanspub.34695-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Huang, D.T., et al. (2018) Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. New England Journal of Medicine, 379, 236-249.</mixed-citation></ref><ref id="hanspub.34695-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Haubitz, S., Mueller, B. and Schuetz, P. (2013) Streamlining Antibiotic Therapy with Procalcitonin Protocols: Consensus and Controversies. Expert Review of Respiratory Medicine, 7, 145-157. &lt;br&gt;https://doi.org/10.1586/ers.13.6</mixed-citation></ref><ref id="hanspub.34695-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Lindstrom, S.T. and Wong, E.K. (2014) Procalcitonin, a Valuable Biomarker Assisting Clinical Decision-Making in the Management of Community-Acquired Pneumonia. Journal of Internal Medicine, 44, 390-397. &lt;br&gt;https://doi.org/10.1111/imj.12374</mixed-citation></ref><ref id="hanspub.34695-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Schuetz, P., Raad, I. and Amin, D.N. (2013) Using Procalcitonin-Guided Algorithms to Improve Antimicrobial Therapy in ICU Patients with Respiratory Infections and Sepsis. Current Opinion in Critical Care, 19, 453-460. &lt;br&gt;https://doi.org/10.1097/MCC.0b013e328363bd38</mixed-citation></ref><ref id="hanspub.34695-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Muroi, C., et al. (2013) Correlation among Systemic Inflammatory Parameter, Occurrence of Delayed Neurological Deficits, and Outcome after Aneurysmal Subarachnoid Hemorrhage. Neurosurgery, 72, 367-375. &lt;br&gt;https://doi.org/10.1227/NEU.0b013e31828048ce</mixed-citation></ref><ref id="hanspub.34695-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Festic, E., et al. (2014) The Utility of Serum Procalcitonin in Distinguishing Systemic Inflammatory Response Syndrome from Infection after Aneurysmal Subarachnoid Hemorrhage. Journal of Neurocritical Care, 20, 375-381. &lt;br&gt;https://doi.org/10.1007/s12028-014-9960-4</mixed-citation></ref><ref id="hanspub.34695-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">朱丹化, 叶盛, 陈贤斌, 等. 降钙素原在神经外科重症患者术后合并感染中的表达及价值[J]. 浙江医学, 2015, 37(8): 647-649.</mixed-citation></ref><ref id="hanspub.34695-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">王广涛. 血清降钙素原检测对脑外伤术后颅内感染的预估价值及其与病情严重程度的相关关系[J]. 中国医师杂志, 2017(11): 1731-1733.</mixed-citation></ref><ref id="hanspub.34695-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">黄永福, 陈志斌, 陈国锋. 重型及特重型颅脑损伤患者降钙素原升高的影响因素分析[J]. 中华创伤杂志, 2017(5): 430-432.</mixed-citation></ref></ref-list></back></article>